Anelize Rivadeneira
Adult Health · Pinellas Park, FLNPI 1275230674
Payments from drug & device makers
Across 163 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Theratechnologies Inc.$392
- GSK$348
- Merck$314
- Lilly USA, LLC$58
- plus $373 from 13 others
What the payments were for
- Food & beverage$4,478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 67 | $1,534 |
| Viiv Healthcare Company | 50 | $1,459 |
| Theratechnologies Inc. | 10 | $392 |
| GSK | 3 | $348 |
| Merck | 13 | $314 |
| Lilly USA, LLC | 2 | $58 |
| Napo Pharmaceuticals Inc | 2 | $46 |
| AbbVie | 2 | $41 |
| Pfizer | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Vertex | 1 | $21 |
| Antares Pharma, Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,478 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 142 | $556,786 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $81,346 |
| TivicayDolutegravir Sodium | 23 | $70,587 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $57,308 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $47,442 |
| PrezcobixDarunavir/Cobicistat | 14 | $32,810 |
| ValacyclovirValacyclovir Hcl | 20 | $495 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $492 |
| Gabapentin | 22 | $186 |
| Omeprazole | 11 | $142 |
| Metoprolol Succinate | 17 | $104 |
| Atorvastatin Calcium | 27 | $90 |
| Amlodipine Besylate | 26 | $80 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 16 | $74 |
| Tamsulosin Hcl | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $1,534 | $556,786142 claims |
| Viiv Healthcare CompanyTivicay, Triumeq | $1,459 | $118,02936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Pinellas Park
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.